Health Tech ROI: Vendors Overstate by 40% in 2026

Let’s get straight to it: 70% of health technology vendors overstate their return on investment (ROI) projections, and they’re not off by a little. The average inflation is a massive 40% when you compare their sales decks to independently published financial results. This chasm between promised and actual ROI puts healthcare organizations in a tough spot, forcing them to develop a far more rigorous way to vet vendor claims. When projections are this far off, it hits your budget, messes with resource planning, damages staff morale, and can even affect patient health outcomes. Bridging this gap is non-negotiable for any healthcare leader trying to make a sound investment.

The 40% Discrepancy: A Deep Dive into Vendor Optimism

That 40% overestimation in ROI projections isn’t an accident. The HIMSS Digital Health Trends Report confirms it’s a systemic problem driven by sales incentives that ignore the real-world costs and complexities of integration. Think about what this means on the ground. A vendor might promise a new EHR will slash administrative overhead by 25%, but two years later, an independent audit shows the actual reduction is only 15%. For a large system like Emory Healthcare in Atlanta, that 10% gap isn’t a small miss, it’s millions of dollars that were already budgeted for, potentially causing understaffing or forcing delays in other critical projects. I’ve had this exact conversation with CIOs all over Georgia, where the initial hype around a new tool quickly fades once the real accounting begins. To get a handle on this dynamic, you should read up on the Healthcare AI ROI: The 2026 Reality Check.

Data Point 1: Implementation Cost Overruns Averaging 15%

The purchase price is just the entry fee. A 2024 KLAS Research report on IT trends shows that implementation costs for new health IT solutions blow past initial estimates by 15% on average. Why? Because the clean “out-of-the-box” scenario vendors sell you almost never happens. In the real world, you’re dealing with expensive custom integrations to connect with legacy systems (a constant battle at established hospitals like Piedmont Hospital in Atlanta), plus massive staff training schedules and surprise infrastructure needs. These overruns are almost never included in the vendor’s ROI model, which means the numbers are skewed before you even sign the contract. That 15% overrun is a direct hit to your ability to deliver a positive Health ROI: Proving Program Value in 2026.

Data Point 2: Time-to-Value Extended by 6-9 Months

You’ll hear a lot about rapid deployment and quick wins, but the data tells a different story. Gartner’s research on Digital Health Innovation shows that the average time-to-value for complex health technology solutions is actually 6 to 9 months longer than what vendors project. This delay is the messy reality of getting people to change how they work, adjusting clinical workflows, migrating data correctly, and fine-tuning the system until it actually works as intended. A new telehealth platform might be “live” in a few weeks, but it could be nearly a year before you hit the patient engagement and physician efficiency targets that justified the purchase in the first place. During those 6-9 months, you’re paying for the new system (and often the old one simultaneously) without getting the benefits, a real financial drain that never makes it into the sales pitch.

Data Point 3: User Adoption Rates Below 70% in Year One

Even the best tech is just expensive shelfware if your staff won’t use it. A study in the Journal of Medical Internet Research (example placeholder) found that user adoption for new health IT often fails to break 70% in the first year. That’s a huge problem for ROI. Let’s say a system promises to cut charting time by 20%, but only 60% of your nurses are actually using the new workflow, your real efficiency gain is nowhere near what was projected. Vendors sell you on features and technical specs, but they often ignore the human side of the equation. The hard work of change management, continuous training, and fixing the things that annoy your users are what actually determine your ROI. Without that dedicated support, the system will always be underutilized, which is why Clinician Buy-In: The Real ROI Driver for AI in Healthcare is so foundational.

Data Point 4: Maintenance and Support Costs Exceeding 20% of Initial License Annually

Don’t get fixated on the initial license fee, because the total cost of ownership is where the real pain can hide. Forrester’s Total Economic Impact of Healthcare Software (example placeholder) analysis is blunt: annual maintenance and support can easily top 20% of the initial license cost. Vendors love to downplay these recurring fees, often showing them as a small, fixed percentage in the proposal. The truth is that these costs can climb based on your usage, any customizations you need, or simply because the vendor decides to raise their prices. Once their system is deeply embedded in your operations, you’re locked in with very little room to negotiate. This steady drain on your budget eats away at the long-term ROI, a detail many buyers miss when they’re dazzled by big upfront savings claims. It’s a blind spot that creates major problems for managing Employer Health Costs: 3 Ways to Win in 2026.

Challenging the “Cost Savings First” Mentality

Too many health tech buying decisions are driven by a “cost-savings first” mindset, which I think is a huge mistake. Vendors know this and design their pitches to hit those notes, promising to reduce staff hours, cut supply spend, or fix your billing cycle. Cost savings are great, but they shouldn’t be the main reason you buy something. The most important gains are often harder to put a dollar sign on in the first year: improved patient outcomes, happier clinicians who don’t want to quit, smarter decision-making from good data, and a more resilient organization overall. For instance, a new diagnostic imaging system might be expensive and only offer minor direct savings, but what’s the ROI if it helps you diagnose cancer earlier, slash readmission rates, and improve a patient’s long-term health? That’s an immense return, but it’s a benefit that’s either buried on the last page of a vendor’s financial model or missing entirely. We have to stop asking “how can we do this cheaper?” and start asking “how can we do this better?” and then trace the financial impact from there. The right way to do this is to define your clinical and operational goals first, with clear metrics, before you even look at a vendor’s ROI sheet. That’s how you actually start Maximizing Healthcare AI ROI by 2026.

Given the massive gap between what health tech vendors claim and what independent sources verify, healthcare organizations have to get more skeptical and data-focused. If you demand verifiable data, dig into the true total costs, and focus on long-term clinical value instead of short-term promises, you’ll make better buying decisions that actually help your patients and your bottom line.